Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow, with on-market solutions including BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, and BioXp Select kits. The company has growing collaborations with premier academic research institutions, emerging start-ups to nearly all of the Top 25 Biopharma companies.
Cyborg Score Rationale
Telesis Bio operates in the high-growth synthetic biology sector with established market presence and broad customer base spanning academic and pharmaceutical institutions. However, the company faces competitive pressure from larger players and limited market capitalization constrains growth optionality.
Top Insights
Company rebranded from Codex DNA, Inc. to Telesis Bio Inc. in November 2022, signaling strategic repositioning in synthetic biology segment
Telesis Bio holds a license agreement with Regeneron Pharmaceuticals, Inc., validating platform adoption by major pharma
The company serves government institutions, contract research organizations, and synthetic biology companies, providing revenue diversification